Tenaya Therapeutics Reports Q4 and Full Year 2025 Results: Strong Clinical Progress, Strategic Collaboration, and Extended Cash Runway
Key Highlights from Tenaya Therapeutics’ Report
- Promising clinical data reported for lead gene therapy programs TN-201 (for MYBPC3-associated HCM) and TN-401 (for PKP2-associated ARVC)
- Significant pipeline progress with TN-301, a selective HDAC6 inhibitor, showing preclinical efficacy in Duchenne Muscular Dystrophy (DMD) models
- New strategic collaboration with Alnylam Pharmaceuticals, offering potential for over \$1.1 billion in milestone payments
- Successful financing in December 2025 generates net proceeds of \$55.8 million, extending cash runway into the second half of 2027
- R&D and G&A expenses decreased year-over-year; net loss narrowed
Detailed Business and Program Updates
TN-201: Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)
- In November 2025, Tenaya presented encouraging interim data from the MyPEAK-1 Phase 1b/2 trial, covering both 3E13 vg/kg (Cohort 1) and 6E13 vg/kg (Cohort 2) doses.
- No dose-limiting toxicities observed, and patients successfully tapered off immunosuppressive medications.
- Substantial increase in MyBP-C protein levels in both cohorts, with higher increases correlating to the higher dose.
- Most patients experienced improvements in biomarkers, hypertrophy measures, and symptoms, with all efficacy-assessed patients now at New York Heart Association Class I.
- Data was presented at the 2025 American Heart Association sessions and published in Cardiovascular Research.
- Enrollment resumed in January 2026 after protocol amendments aligned with FDA input.
- 2026 milestones:
- Ongoing enrollment in the 6E13 vg/kg expansion cohort
- Reporting interim Cohort 2 and Cohort 1 updates in H1 2026
- One-year Cohort 2 and two-year Cohort 1 results in H2 2026
- Update on regulatory alignment for pivotal plans in H2 2026
TN-401: Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
- December 2025: Initial data from the RIDGE-1 Phase 1b/2 trial showed TN-401 was well tolerated at 3E13 vg/kg (Cohort 1), with no dose-limiting toxicities or serious adverse events.
- Biopsies at eight weeks post-treatment demonstrated robust transduction and RNA expression. PKP2 protein levels increased by an average of 10% in the first two patients.
- Clinically meaningful improvements in electrical instability (PVCs and NSVTs) observed in patients with over six months follow-up.
- The Data and Safety Monitoring Board endorsed continued expansion at both dose levels in January 2026.
- 2026 milestones:
- Continued enrollment in the 6E13 vg/kg expansion cohort
- One-year Cohort 1 and initial Cohort 2 data in H1 2026
- Interim Cohort 2 data in H2 2026
- Regulatory alignment update on pivotal plans by year-end
TN-301: Small Molecule HDAC6 Inhibitor for HFpEF, DMD, and Related Diseases
- Preclinical data presented at the 2026 Muscular Dystrophy Association Congress showed TN-301 outperformed givinostat in mdx mouse models of DMD.
- TN-301 at 3 mg/kg restored grip strength to wild-type levels within five weeks, while givinostat did not.
- Functional improvements included reduced circulating creatine kinase and favorable gene expression changes.
- In human DMD iPSC-derived cardiomyocytes, TN-301 corrected calcium and mitochondrial dysfunctions; givinostat worsened these parameters.
- 2026 plans: Advance TN-301 to clinical trials, with HFpEF and DMD among the most promising indications.
Strategic and Financial Updates
Alnylam Collaboration
- Tenaya entered a multi-target research collaboration with Alnylam Pharmaceuticals to identify and validate genetic targets for cardiovascular diseases.
- Upfront payment of up to \$10 million, eligibility for over \$1.1 billion in milestones, and reimbursement for research costs.
- Alnylam will handle development, manufacturing, regulatory, and commercialization of resulting therapeutics.
December 2025 Financing
- Closed an underwritten public offering of 50 million units at \$1.20 each (1 share + 1 warrant at \$1.50/share), generating \$55.8 million in net proceeds.
- Cash runway extended into H2 2027 thanks to this offering and anticipated Alnylam upfront payment.
Financial Highlights
- Cash, cash equivalents, and marketable securities: \$100.5 million as of December 31, 2025 (up from \$61.4 million at end of 2024).
- R&D expenses: \$68.6 million for 2025 (down from \$86.7 million in 2024).
- G&A expenses: \$24.7 million for 2025 (down from \$29.2 million in 2024).
- Net loss for 2025: \$90.6 million, or \$0.59 per share (improved from \$111.1 million, or \$1.31 per share, in 2024).
- Weighted-average shares outstanding for 2025: ~153 million (up from ~85 million in 2024, reflecting the recent financing and dilution).
Potential Share Price Movers & Investor Considerations
- Positive clinical updates from both TN-201 and TN-401 signal progress toward potential pivotal trials and future regulatory submissions.
- Alnylam partnership could provide significant non-dilutive capital and validates Tenaya’s platform, expanding the addressable market and pipeline value.
- Reduced operating expenses and net loss improve financial sustainability and extend the cash runway, reducing near-term financing risk.
- Upcoming milestones in 2026 (clinical data, regulatory updates, and partnership progress) represent potential catalysts for share price movement.
- Any delays or negative clinical/regulatory outcomes, or changes in the Alnylam collaboration, could be downside risks to valuation.
About Tenaya Therapeutics
Tenaya is a clinical-stage biotech focused on curative therapies for heart disease. Its pipeline includes TN-201 (gene therapy for MYBPC3-associated HCM), TN-401 (gene therapy for PKP2-associated ARVC), TN-301 (HDAC6 inhibitor for heart failure and muscle diseases), and multiple preclinical programs.
Contacts
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The information above is based on company-reported data and forward-looking statements, which are subject to risks and uncertainties.
View Tenaya Therapeutics, Inc. Historical chart here
